Press Release: Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
Dow Jones Institutional News; New York. 05 Nov 2023.

You might have access to the full article...
Try and log in through your library or institution to see if they have access to the full text.





